Metformin Repurposing for Parkinson Disease Therapy: Opportunities and Challenges

• Published in: International journal of molecular sciences 2021-12, Vol.23 (1), p.398
• Main Authors: Agostini, Francesco, Masato, Anna, Bubacco, Luigi, Bisaglia, Marco
• Format: Article
• Language: English
• Subjects: AMPK; Animals; Antidiabetics; Autophagy; Autophagy - drug effects; bioavailability; Biological Availability; Diabetes; Diabetes mellitus; Diabetes mellitus (non-insulin dependent); Dopamine receptors; Drug Repositioning; Drugs; Epidemiology; Homeostasis; Humans; Kinases; Metformin; Metformin - administration & dosage; Metformin - adverse effects; Metformin - pharmacology; Metformin - therapeutic use; Mitochondria; Neurodegeneration; Neurons; Neuroprotection; Neuroprotective Agents - administration & dosage; Neuroprotective Agents - pharmacology; Neuroprotective Agents - therapeutic use; Parkinson disease; Parkinson Disease - drug therapy; Parkinson's disease; Patients; Proteins; Review; Synuclein
• ISSN: 1422-0067; 1661-6596; 1422-0067
• DOI: 10.3390/ijms23010398

Parkinson disease (PD) is a severe neurodegenerative disorder that affects around 2% of the population over 65 years old. It is characterized by the progressive loss of nigrostriatal dopaminergic neurons, resulting in motor disabilities of the patients. At present, only symptomatic cures are available, without suppressing disease progression. In this frame, the anti-diabetic drug metformin has been investigated as a potential disease modifier for PD, being a low-cost and generally well-tolerated medication, which has been successfully used for decades in the treatment of type 2 diabetes mellitus. Despite the precise mechanisms of action of metformin being not fully elucidated, the drug has been known to influence many cellular pathways that are associated with PD pathology. In this review, we present the evidence in the literature supporting the neuroprotective role of metformin, i.e., autophagy upregulation, degradation of pathological α-synuclein species, and regulation of mitochondrial functions. The epidemiological studies conducted in diabetic patients under metformin therapy aimed at evaluating the correlation between long-term metformin consumption and the risk of developing PD are also discussed. Finally, we provide an interpretation for the controversial results obtained both in experimental models and in clinical studies, thus providing a possible rationale for future investigations for the repositioning of metformin for PD therapy.